Azathioprine, adverse reactions - seriousCyclophosphamide, adverse reactions - seriousImmunosuppressants, adverse reactions - seriousMycophenolate-mofetil, adverse reactions - seriousNon-Hodgkin's-lymphoma, drug-inducedPrednisone, adverse reactions - serious...
Kaposi's sarcoma, non-Hodgkin's lymphoma, Hodgkin's disease, and squamous cell carcinoma are among the malignancies seen with increased frequency in patients infected with HIV. The outlook for patients with these malignancies has improved significantly with the utilization of highly active antiretroviral...
ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma Amandeep Aujla1, Ravijot Aujla2 and Delong Liu1,3* Open Access Abstract B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) frequently express CD19, CD20 and CD22 on the cell ...
Non-Hodgkin's Lymphoma Karen M. Winkfield, ... Mary K. Gospodarowicz, in Clinical Radiation Oncology (Fourth Edition), 2016 Primary Mediastinal B-Cell Lymphoma Primary mediastinal B-cell lymphoma (PMBL) is a subtype of DLBCL arising in the mediastinum and the presumed cellular origin is from ...
CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for CAR-T Cell Therapy for Non-Hodgkin Lymphoma Cellular Biomedicine Group Inc. announced that the Food and Drug Administration (FDA) granted ...
CD30 and programmed cell death protein 1 (PD-1) are two ideal therapeutic targets in classical Hodgkin lymphoma (cHL). The CD30 antibody-drug conjugate (ADC) brentuximab vedotin and the PD-1 antibodies nivolumab and pembrolizumab are highly efficacious in treating relapsed and/or refractory cHL....
non-Hodgkin; extranodal; tonsil; radiotherapy Abstract BACKGROUND. The purpose was to evaluate the prognostic factors and treatment outcome of Indian patients with primary diffuse large B-cell lymphoma (DLBCL) of the tonsil treated at a single institution. METHODS. In all, 121 patients with DLBCL...
B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) frequently express CD19, CD20 and CD22 on the cell surfaces. Immunotherapeutic agents including antibodies and chimeric antigen receptor T cells are widely studied in clinical trial
Avyakta Kallam, MBBS and Julie Vose MD, MBA, review available treatment options for patients with mantle cell lymphoma. Introduction Mantle cell lymphoma (MCL) is a disease of older patients with a median age of 65 years. It accounts for 5% to 7% of all non-Hodgkin lymphoma (NHL)...
Background Because procarbazine is not available in the mainland of China, a risk-adapted chemotherapy without the drug was adopted for children with Hodgkin lymphoma (HL) in two tertiary referral centers for childhood cancer in Shanghai. The objective of the present study was to obtain the resul...